Sarepta price target raised to $144 from $137 at Credit Suisse

Credit Suisse raised the firm’s price target on Sarepta to $144 from $137 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 earnings with the announcement that FDA does not plan to hold an advisory committee for SRP-9001 driving shares solidly higher post-close. Given the definitively positive management tone around this update, Credit Suisse incrementally raises PoS for the program to 90%.